ReviewRSC advances2025
Diverse chemotypes of polyketides as promising antimicrobial agents: latest progress.
Review in RSC advances, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed.
- Sustainable Biocatalytic Cascades: A Versatile Tool in the Synthesis of Natural Products With Therapeutic Potential.Chembiochem : a European journal of chemical biology · 2026Review
- Tobacco intercropping with Allium crops reshapes soil microbiome-metabolome interactions and improves plant health and tobacco leaf quality.BMC plant biology · 2026Article
- Natural Products and Antimicrobial Nanoparticles Against Methicillin-ResistantPharmaceutics · 2026Review
- The neonatal and maternal nasal microbiomes are compositionally diverse and functionally distinct within 24 hours of birth.Frontiers in cellular and infection microbiology · 2026Article
- Bacterial secondary metabolites as resistance-modifying adjuvants: microbial origins, molecular mechanisms, and translational relevance.Frontiers in microbiology · 2026Review
- A Comprehensive Review of Plant and Microbial Natural Compounds as Sources of PotentialBiotech (Basel (Switzerland)) · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Microorganisms, including bacteria, viruses, fungi, and protozoa, significantly impact human health by causing infections that can lead to serious health issues, including mortality and morbidity. Antimicrobials, including antibacterials, anti-virals, anti-fungals, and anti-parasitics, effectively prevent and treat infections in humans and animals. However, pathogens have developed resistance to these antimicrobials, enabling them to survive and persist even in the presence of antibiotics. There is a pressing need to develop new antibiotics with different mechanisms of action to combat infectious diseases effectively. Nature provides a vast therapy and drug discovery resource, offering unparalleled chemical diversity and structural complexity. Among these resources, polyketide synthase machinery produces secondary metabolites in plants, animals, marine organisms, and fungi, significantly contributing to drug discovery. Notably, polyketides exhibit diverse chemotypes, which can facilitate the discovery of antimicrobial drugs. Also, polyketide-based drugs, including anti-bacterial, anti-fungal, and anti-parasitic, have been approved for treating various infectious diseases. This review summarizes recently identified natural polyketides with potential antimicrobial activities.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.